AGL
Agilon Health, Inc.
AGL offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over AGL overall, supported by lower modeled downside and stronger fundamentals.
AGL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Unavailable |
AGL's revenue and profitability are currently stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AGL PE Valuation
AGL has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 59x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AGL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect AGL to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.86 | — |
| Q3 2026 | -$5.46 | +$13.21 |
| Q2 2026 | -$14.08 | +$5.09 |
| Q1 2026 | -$21.43 | -$6.70 |
| Q4 2025 | -$23.63 | -$7.80 |
| Q3 2025 | -$18.67 | +$4.76 |
| Q2 2025 | -$19.17 | -$0.88 |
| Q1 2025 | -$14.73 | +$2.69 |
| Q4 2024 | -$15.83 | +$0.22 |
AGL is still losing money, but far less than before: $5.46 per share over the past year, against $27.25 at its worst in late 2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AGL on earnings quality, reporting a profit while its opponent remains loss making.
AGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +5.9% |
| Q2 2026 | $1.5B | +7.2% |
| Q1 2026 | $1.4B | -7.3% |
| Q4 2025 | $1.6B | +3.1% |
| Q3 2025 | $1.4B | -1.1% |
| Q2 2025 | $1.4B | -5.9% |
| Q1 2025 | $1.5B | -4.5% |
| Q4 2024 | $1.5B | +87% |
AGL's revenue grew through 2024 and has held roughly level since: $1.5B last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.6% | +11 points |
| Q2 2026 | 0.8% | +9.1 points |
| Q1 2026 | 0.3% | +1.7 points |
| Q4 2025 | -12% | -5.3 points |
| Q3 2025 | -9.2% | 0 points |
| Q2 2025 | -8.3% | -5.4 points |
| Q1 2025 | -1.4% | -1 points |
| Q4 2024 | -7.1% | +13 points |
AGL's operating margin was 1.6% last quarter, up 11 points from the same quarter a year ago, near the top of its range since 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AGL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AGL on profitability, with a higher operating margin.
AGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.6M | +$67.9M |
| Q2 2026 | -$60.7M | -$22.4M |
| Q1 2026 | $20.6M | +$56.5M |
| Q4 2025 | -$23.5M | -279% |
| Q3 2025 | -$21.3M | -$10.1M |
| Q2 2025 | -$38.3M | -$16.3M |
| Q1 2025 | -$35.8M | +$15.1M |
| Q4 2024 | $13.2M | +$78.3M |
AGL has burned cash in almost every quarter: −$17M over the past year, against −$82M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AGL on cash generation, producing positive trailing cash flow while its opponent burns cash.
AGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +475K shares |
| 1 year | +6.7% | +1.1M shares |
| 3 years | +9% | +1.5M shares |
| 5 years | +13% | +2M shares |
| Available history | +15% | +2.3M shares |
AGL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q4 2021 | — |
| Q1 2021 | — |
| Q3 2020 | $6.7M |
| Q2 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AGL Net Leverage
AGL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.8 | Neutral |
| Stochastic | 58.3 | Neutral |
AGL's weekly RSI is 64 (neutral) and its Stochastic is 58 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AGL PE vs Healthcare Sector
AGL has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $91.3 | 21% above |
| 20 week MA | $96.3 | 15% above |
| 50 week MA | $61.7 | 79% above |
| 100 week MA | $59.8 | 85% above |
| 200 week MA | $181.6 | 39% below |
AGL has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 39% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AGL on trend strength, trading above more of its moving averages.
AGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $750.0 | $684.8 | -8.7% |
| 2022 | $684.8 | $407.0 | -41% |
| 2023 | $407.0 | $313.8 | -23% |
| 2024 | $313.8 | $47.5 | -85% |
| 2025 | $47.5 | $18.2 | -62% |
| 2026 YTD | $18.2 | $110.3 | +508% |
AGL has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.